Cargando…

1283. High Dose Minocycline for the Treatment of Acinetobacter Infections

BACKGROUND: Acinetobacter (ACB) infections are difficult to treat due to increasing drug resistance. The aim of this study is to evaluate the effectiveness of high-dose (HD) minocycline (MIN) 200mg q12h for the treatment of ACB infections METHODS: This is a retrospective study of pts with ACB from 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbin, Shelbye R, Ammar, Amina, Gumbleton, Ryan, Zhao, Jing, Olson, Shannon, Smith, Stephanie M, Scipione, Marco R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644103/
http://dx.doi.org/10.1093/ofid/ofab466.1475
_version_ 1784610008783126528
author Herbin, Shelbye R
Ammar, Amina
Gumbleton, Ryan
Zhao, Jing
Olson, Shannon
Smith, Stephanie M
Scipione, Marco R
author_facet Herbin, Shelbye R
Ammar, Amina
Gumbleton, Ryan
Zhao, Jing
Olson, Shannon
Smith, Stephanie M
Scipione, Marco R
author_sort Herbin, Shelbye R
collection PubMed
description BACKGROUND: Acinetobacter (ACB) infections are difficult to treat due to increasing drug resistance. The aim of this study is to evaluate the effectiveness of high-dose (HD) minocycline (MIN) 200mg q12h for the treatment of ACB infections METHODS: This is a retrospective study of pts with ACB from 1/1/19 to 10/31/20. Exclusions included non-susceptibility to MIN, age < 18 yrs, hospice care w/in 72 hrs of culture, or urine source. Use of HD MIN (IV or PO), was compared to alternative treatment (AT). Clinical and micro success at the end of therapy (EOT) was evaluated. Clinical success was elimination or improvement in signs and symptoms of infection. Micro success was eradication of ACB from the same site of infection at EOT. Length of stay (LOS), 30-day readmission (with or without ACB), isolation of a MIN non-susceptible ACB within 30 days of EOT, and adverse events related to MIN, were evaluated. RESULTS: A total of 320 pts were screened with the most common exclusion being MIN non-susceptible isolate. Of the 204 pts included, 38 received HD MIN and 166 received AT. The most common were cefepime (53/166) and meropenem (36/166). Median age (IQR) was 41 (30-50) yrs for HD MIN vs. 40 (27-48) yrs for AT. Both groups were mostly male (HD MIN: 63% vs. AT: 60%) and respiratory was the most common site (HD MIN: 61% vs. AT: 60%). HD MIN group had 74% of cultures that were polymicrobial vs. 86% in AT group. Lack of clinical response at the EOT occurred in 42% of pts on HD MIN and 37% on AT. Infection related mortality occurred in 24% on HD MIN vs. 15% on AT. In HD MIN group, 16 pts had a repeat culture from the same site after treatment with 25% still positive for ACB. In the AT group 61 pts had a repeat culture and 28% were positive for ACB. Duration of treatment (9 [6-11] days vs. 10 [2-18] days) and LOS (16 [18.25-26.75] vs. 29 [14-49]) were shorter in the HD MIN group. There was only one adverse event reported with the use of HD MIN CONCLUSION: Pts in the HD MIN group had shorter treatment duration and a shorter LOS. Pts who received HD MIN had a lower rate of clinical cure and a higher mortality rate compared to pts in the AT group. Reasons for this difference will need to be investigated further. HD MIN should be reserved for pts who are unable to tolerate other treatment options or who have an ACB resistant to other treatment options. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-8644103
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86441032021-12-06 1283. High Dose Minocycline for the Treatment of Acinetobacter Infections Herbin, Shelbye R Ammar, Amina Gumbleton, Ryan Zhao, Jing Olson, Shannon Smith, Stephanie M Scipione, Marco R Open Forum Infect Dis Poster Abstracts BACKGROUND: Acinetobacter (ACB) infections are difficult to treat due to increasing drug resistance. The aim of this study is to evaluate the effectiveness of high-dose (HD) minocycline (MIN) 200mg q12h for the treatment of ACB infections METHODS: This is a retrospective study of pts with ACB from 1/1/19 to 10/31/20. Exclusions included non-susceptibility to MIN, age < 18 yrs, hospice care w/in 72 hrs of culture, or urine source. Use of HD MIN (IV or PO), was compared to alternative treatment (AT). Clinical and micro success at the end of therapy (EOT) was evaluated. Clinical success was elimination or improvement in signs and symptoms of infection. Micro success was eradication of ACB from the same site of infection at EOT. Length of stay (LOS), 30-day readmission (with or without ACB), isolation of a MIN non-susceptible ACB within 30 days of EOT, and adverse events related to MIN, were evaluated. RESULTS: A total of 320 pts were screened with the most common exclusion being MIN non-susceptible isolate. Of the 204 pts included, 38 received HD MIN and 166 received AT. The most common were cefepime (53/166) and meropenem (36/166). Median age (IQR) was 41 (30-50) yrs for HD MIN vs. 40 (27-48) yrs for AT. Both groups were mostly male (HD MIN: 63% vs. AT: 60%) and respiratory was the most common site (HD MIN: 61% vs. AT: 60%). HD MIN group had 74% of cultures that were polymicrobial vs. 86% in AT group. Lack of clinical response at the EOT occurred in 42% of pts on HD MIN and 37% on AT. Infection related mortality occurred in 24% on HD MIN vs. 15% on AT. In HD MIN group, 16 pts had a repeat culture from the same site after treatment with 25% still positive for ACB. In the AT group 61 pts had a repeat culture and 28% were positive for ACB. Duration of treatment (9 [6-11] days vs. 10 [2-18] days) and LOS (16 [18.25-26.75] vs. 29 [14-49]) were shorter in the HD MIN group. There was only one adverse event reported with the use of HD MIN CONCLUSION: Pts in the HD MIN group had shorter treatment duration and a shorter LOS. Pts who received HD MIN had a lower rate of clinical cure and a higher mortality rate compared to pts in the AT group. Reasons for this difference will need to be investigated further. HD MIN should be reserved for pts who are unable to tolerate other treatment options or who have an ACB resistant to other treatment options. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2021-12-04 /pmc/articles/PMC8644103/ http://dx.doi.org/10.1093/ofid/ofab466.1475 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Herbin, Shelbye R
Ammar, Amina
Gumbleton, Ryan
Zhao, Jing
Olson, Shannon
Smith, Stephanie M
Scipione, Marco R
1283. High Dose Minocycline for the Treatment of Acinetobacter Infections
title 1283. High Dose Minocycline for the Treatment of Acinetobacter Infections
title_full 1283. High Dose Minocycline for the Treatment of Acinetobacter Infections
title_fullStr 1283. High Dose Minocycline for the Treatment of Acinetobacter Infections
title_full_unstemmed 1283. High Dose Minocycline for the Treatment of Acinetobacter Infections
title_short 1283. High Dose Minocycline for the Treatment of Acinetobacter Infections
title_sort 1283. high dose minocycline for the treatment of acinetobacter infections
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644103/
http://dx.doi.org/10.1093/ofid/ofab466.1475
work_keys_str_mv AT herbinshelbyer 1283highdoseminocyclineforthetreatmentofacinetobacterinfections
AT ammaramina 1283highdoseminocyclineforthetreatmentofacinetobacterinfections
AT gumbletonryan 1283highdoseminocyclineforthetreatmentofacinetobacterinfections
AT zhaojing 1283highdoseminocyclineforthetreatmentofacinetobacterinfections
AT olsonshannon 1283highdoseminocyclineforthetreatmentofacinetobacterinfections
AT smithstephaniem 1283highdoseminocyclineforthetreatmentofacinetobacterinfections
AT scipionemarcor 1283highdoseminocyclineforthetreatmentofacinetobacterinfections